Artivion Appoints Lance Berry as COO, Raises Earnings Guidance

Artivion, a medical technology company, has reported Q2 2025 revenue of $113M, a 15% increase from the previous year and beating analyst expectations. The company also raised its earnings guidance for the year ended December 2025. Artivion has appointed Lance Berry as its new Chief Operating Officer.

Artivion Inc. (NYSE: AORT) has reported robust second-quarter 2025 earnings, with revenue jumping 15% year-over-year to $113M, surpassing analyst expectations. The company also raised its full-year earnings guidance for the year ended December 2025. Additionally, Artivion has appointed Lance Berry as its new Chief Operating Officer.

Key highlights from the Q2 2025 report include:

- Revenue Growth: Artivion’s Q2 2025 revenue of $113M represents a 15% increase over the previous year, driven by strong product performance across its portfolio, particularly in the On-X mechanical valves and aortic stent grafts [1].
- Earnings Guidance: The company raised its earnings guidance for the year, reflecting its optimism about future growth prospects.
- New Leadership: Lance Berry has been appointed as the new Chief Operating Officer, bringing extensive operational experience to the role.

The company’s Q2 2025 performance showcases accelerating growth across its product lines, with On-X and stent grafts achieving 24% year-over-year growth on a GAAP basis. Preservation services and surgical sealants also contributed to the overall revenue increase, albeit at a more modest pace. Geographically, North America led growth at 18% year-over-year, followed by Asia-Pacific at 15% and EMEA (Europe, Middle East, and Africa) at 10% on a constant currency basis.

Artivion’s financial performance was bolstered by improved gross margins and EBITDA expansion. The company’s non-GAAP gross margin improved to 65.1%, and non-GAAP diluted earnings per share came in at $0.24. Free cash flow also showed remarkable improvement, reaching $11.7 million, a 223.7% increase from Q2 2024.

The appointment of Lance Berry as the new Chief Operating Officer is expected to further strengthen Artivion’s operational efficiency and drive future growth initiatives. Berry brings a wealth of experience in operational management and strategic planning, which could be instrumental in navigating the company’s growth trajectory.

Investors and financial professionals should closely monitor Artivion’s progress in the coming quarters, as the company continues to expand its product offerings and explore new markets. The recent financial results and strategic appointments indicate a positive outlook, with the potential for further growth in the medical technology sector.

References:
[1] https://stockstotrade.com/news/artivion-inc-com-aort-news-2025_08_09/